search
Wegovy
Trends
- 1
A new study suggests that people who discontinue GLP-1 medications, such as Ozempic and Wegovy, may face an increased risk of heart attack and stroke. The findings add to ongoing debate about how long patients should stay on these widely used weight-loss and diabetes drugs, and whether the cardiovascular benefits persist after stopping treatment.
- 2
GLP-1 weight-loss drugs such as Ozempic and Wegovy are reshaping sleep medicine, with clinicians reporting improved sleep apnea symptoms in patients losing significant weight and drugmakers seeking apnea indications. Sleep specialists are debating whether medication could reduce reliance on CPAP machines, while researchers caution that long-term effects on sleep disorders remain largely unstudied.
- 3Weight-loss jab maker's Vogue World sponsorship sparks concern▼‘It’s problematic’: concern as weight-loss jab maker sponsors Vogue World event
Novo Nordisk, the maker of weight-loss injection Wegovy, is sponsoring Vogue World, and the partnership is drawing criticism from commentators who call it problematic. Critics argue that having a pharmaceutical weight-loss brand fund a major fashion event risks glamorising slimming jabs and reinforcing harmful body-image pressures in an industry already criticised for promoting thinness.